Selpercatinib and Body Composition

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07543887

Acronym

EECRTKI

Enrollment

Registered

2026-04-22

Start date

2024-04-12

Completion date

2026-04-04

Last updated

2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer

Keywords

thyroid

Brief summary

investigation of body composition

Detailed description

investigation of body composition by DXA

Interventions

OTHERobservation in patient under treatment

observation in patient under treatment

DRUGSelpercatinib

observational study of patients under selpercatinib

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Adults (≥18 years old) * Diagnosis of thyroid cancer * Ongoing treatment with selpercatinib

Exclusion criteria

\- Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
Total lean mass assessed by DXA (kg)	Baseline and 12 months	Total lean body mass measured by dual-energy X-ray absorptiometry

Secondary

Measure	Time frame	Description
24-hour energy expenditure (kcal/day)	Baseline and 12 months	Total energy expenditure measured over 24 hours using a whole-room indirect calorimeter

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026